Major difference between Donepezil and A-273 is the side effects. If the two were hypothetically equal, just on less side effects, we would have a new SOC if p2/3 repeats its p2a/b results.
However, we all know Donepezil doesn't work for a year, more like a month or two before the decline starts again.
Plus, we don't know exactly HOW much a-273 does benefit, or as the naysayers say, if it benefits at all, the patient because the dosage isn't optimized across the board. Some need to understand that and not treat this data as "as good as it gets".
We are yet to see just how good a-273 works when given with the correct dosage.
I agree with all of that. "Work" is relative, but sure, it begins to decline after one month to a few months. However, the data we have for 2-73 shows similarly, apart from that uptick at 52 weeks which I don't put too much emphasis on statistically.
I agree on side effects, as I stated below, but the difference between a drug with equal efficacy with few side effects and a drug with a stable MMSE over two years with few side effects is night and day. It's the difference between a drug with real potential and a drug with paradigm shifting blockbuster potential.
I am aware the 2-73 dose is not optimized. I'm working with what is at hand, for the time being. What else is there? I certainly don't see this data as anything other than preliminary and is certainly not "as good as it gets," if that's what you're suggesting.
Re the optimized dosage, what dosage did they put them on for the extension after the 57 weeks? I've seen someone write that they put them all on optimized dosage, but I haven't seen that on the website.